# 2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients

> **NCT06432166** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **MTI Biotech Inc** · enrollment: 48 (estimated)

## Conditions studied

- Alzheimer Disease
- Mild Cognitive Impairment

## Interventions

- **DRUG:** 2-hydroxybenzylamine acetate
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06432166
- **Lead sponsor:** MTI Biotech Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06432166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06432166, "2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06432166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*